Myriad holds monopoly for BRCA1/BRCA2 testing
Myriad Genetics is the only place to go for BRCA1/BRCA2 mutation testing. The Salt Lake City biopharmaceutical company has a monopoly on the test. Its scientists discovered the BRCA1 and BRCA2 genes in 1996 and patented their use for assessing the risk of genetically related cancer.
Myriad Genetics is the only place to go for BRCA1/BRCA2 mutation testing. The Salt Lake City biopharmaceutical company has a monopoly on the test. Its scientists discovered the BRCA1 and BRCA2 genes in 1996 and patented their use for assessing the risk of genetically related cancer.
According to a Myriad spokesperson, 50,000 BRCA1 and BRCA2 genetic tests were performed in 2006, compared with 35,000 in 2005. The firm expects demand to rise again about 43% this year. The automated gene sequencing technology covers 85% to 90% of genetically related breast cancer. Results from about 15 of every 100 tests are positive.
Testing charges vary. It costs $3200 to test the first person in a family, according to Robert Resta, a genetic counselor with Swedish Medical Center in Seattle. Testing first-degree relatives-parents, siblings, and children-costs an additional $400 per person. For Ashkenazi Jews, the test costs about $500 because their susceptibility is based on fewer mutations than the general population, thereby requiring a simpler test, Resta said.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
